J Menopausal Med.  2018 Dec;24(3):176-182. 10.6118/jmm.2018.24.3.176.

Age of Postmenopause Women: Effect of Soy Isoflavone in Lipoprotein and Inflammation Markers

• Barrasa GR
• González Cañete N
• Boasi LE

• KMID: 2455891
• DOI: http://doi.org/10.6118/jmm.2018.24.3.176

Abstract

OBJECTIVES
Menopause is associated with adverse metabolic changes in plasma lipoprotein and inflammation markers. Estrogens have beneficial effects on lipid metabolism and inflammation. Isoflavones (ISO) have structurally similar to estradiol. Our objective was analize the effect of soy-ISO on serum lipid and inflammatory markers (sP-selectin and sCD40L) in postmenopausal women.
METHODS
A 12-week randomized, double-blind, placebo-controlled intervention with soy-ISO (50 mg, twice daily) was conducted in 35 healthy postmenopausal women (55-72 years old). The women were divided in 2 groups: 20 were allocated to soy-ISO, and 15 to a placebo group.
RESULTS
The changes of total cholesterol (TC), triglycerides, low-density lipoproteins-cholesterol (LDL-C), high-density lipoprotein-cholesterol, Apo-A1, sP-selectin and sCD40L in 2 groups before and after 12-week treatment showed no statistical significance. In subgroup analysis, soy-ISO supplementation significantly decreased the levels of TC, LDL-C and sCD40L in women under 65 years old, and with null effects on serum lipid and inflammation markers in women over 65 years old.
CONCLUSIONS
Soy-ISO did not significantly favorable effects on the lipid profile and inflammatory markers in postmenopausal women. However, in women under 65 years of age, soy-ISO significantly decreased the TC, LDL-C and sCD40L, whereas, no effects on lipid profile and inflammation markers in women over 65 years old were observed.

Keyword

Dyslipidemias; Healthy aging; Inflammation; Isoflavones; Postmenopause

MeSH Terms

Cholesterol
Dyslipidemias
Estradiol
Estrogens
Female
Humans
Inflammation*
Isoflavones
Lipid Metabolism
Lipoproteins*
Menopause
Plasma
Postmenopause*
Triglycerides
Cholesterol
Estradiol
Estrogens
Isoflavones
Lipoproteins
Triglycerides

Reference

1. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005; 308:1583–1587.

2. Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during aging: from periphery to brain. Trends Mol Med. 2013; 19:197–209.

3. Chahal HS, Drake WM. The endocrine system and ageing. J Pathol. 2007; 211:173–180.

4. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003; 349:523–534.

5. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280:605–613.

6. Cano A, García-Pérez MA, Tarín JJ. Isoflavones and cardiovascular disease. Maturitas. 2010; 67:219–226.

7. Bertonazzi A, Nelson B, Salvador J, Umland E. The smallest available estradiol transdermal patch: a new treatment option for the prevention of postmenopausal osteoporosis. Womens Health (Lond). 2015; 11:815–824.

8. Munro IC, Harwood M, Hlywka JJ, Stephen AM, Doull J, Flamm WG, et al. Soy isoflavones: a safety review. Nutr Rev. 2003; 61:1–33.

9. Vitale DC, Piazza C, Melilli B, Drago F, Salomone S. Isoflavones: estrogenic activity, biological effect and bioavailability. Eur J Drug Metab Pharmacokinet. 2013; 38:15–25.

10. An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N, Leitman DC. Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem. 2001; 276:17808–17814.

11. Messina M. Soy and health update: Evaluation of the clinical and epidemiologic literature. Nutrients. 2016; 8:E754.

12. Taku K, Umegaki K, Sato Y, Taki Y, Endoh K, Watanabe S. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. 2007; 85:1148–1156.

13. Fujimoto TT, Noda M, Takafuta T, Shimomura T, Fujimura K, Kuramoto A. Expression and functional characterization of the P-selectin glycoprotein ligand-1 in various cells. Int J Hematol. 1996; 64:231–239.

14. Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanaporn P, Schaub RG, et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg. 2003; 38:1075–1089.

15. André P, Hartwell D, Hrachovinová I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A. 2000; 97:13835–13840.

16. Mach F, Schönbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997; 96:396–399.

17. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol. 2000; 20:2322–2328.

18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18:499–502.

19. Allanore Y, Borderie D, Meune C, Lemarechal H, Weber S, Ekindjian OG, et al. Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers. Ann Rheum Dis. 2005; 64:481–483.

20. Miller VT, LaRosa J, Barnabei V, Kessler C, Levin G, Smith-Roth A, et al. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995; 273:199–208.

21. Alwers R, Urdinola J, Onatra W, Sánchez F, Posso H. Changes in normal lipid profile of menopausal women with combined hormone replacement therapy. Comparative clinical trial of two hormonal combinations (conjugated estrogens/medroxyprogesterone acetate versus estradiol valerate/cyproterone acetate). Maturitas. 1999; 32:41–50.

22. Harman SM, Vittinghoff E, Brinton EA, Budoff MJ, Cedars MI, Lobo RA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med. 2011; 124:199–205.

23. Hodis HN, Mack WJ, Shoupe D, Azen SP, Stanczyk FZ, Hwang-Levine J, et al. Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. Menopause. 2015; 22:391–401.

24. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 1998; 139:4252–4263.

25. Oseni T, Patel R, Pyle J, Jordan VC. Selective estrogen receptor modulators and phytoestrogens. Planta Med. 2008; 74:1656–1665.

26. Li J, Liu Y, Wang T, Zhao L, Feng W. Does genistein lower plasma lipids and homocysteine levels in postmenopausal women? A meta-analysis. Climacteric. 2016; 19:440–447.

27. Mangano KM, Hutchins-Wiese HL, Kenny AM, Walsh SJ, Abourizk RH, Bruno RS, et al. Soy proteins and isoflavones reduce interleukin-6 but not serum lipids in older women: a randomized controlled trial. Nutr Res. 2013; 33:1026–1033.

28. Simental-Mendia LE, Gotto AM Jr, Atkin SL, Banach M, Pirro M, Sahebkar A. Effect of soy isoflavone supplementation on plasma lipoprotein(a) concentrations: A meta-analysis. J Clin Lipidol. 2018; 12:16–24.

29. Nagasawa M, Zhu Y, Isoda T, Tomizawa D, Itoh S, Kajiwara M, et al. Analysis of serum soluble CD40 ligand (sCD40L) in the patients undergoing allogeneic stem cell transplantation: platelet is a major source of serum sCD40L. Eur J Haematol. 2005; 74:54–60.

30. Gerdes N, Seijkens T, Lievens D, Kuijpers MJ, Winkels H, Projahn D, et al. Platelet CD40 exacerbates atherosclerosis by transcellular activation of endothelial cells and leukocytes. Arterioscler Thromb Vasc Biol. 2016; 36:482–490.

31. Gresele P, Momi S. Inhibitors of the interaction between von Willebrand factor and platelet GPIb/IX/V. Handb Exp Pharmacol. 2012; 287–309.

32. Enomoto Y, Adachi S, Matsushima-Nishiwaki R, Doi T, Niwa M, Akamatsu S, et al. Thromboxane A(2) promotes soluble CD40 ligand release from human platelets. Atherosclerosis. 2010; 209:415–421.

33. Guerrero JA, Lozano ML, Castillo J, Benavente-García O, Vicente V, Rivera J. Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J Thromb Haemost. 2005; 3:369–376.

34. Muñoz Y, Garrido A, Valladares L. Equol is more active than soy isoflavone itself to compete for binding to thromboxane A(2) receptor in human platelets. Thromb Res. 2009; 123:740–744.

35. Gonzalez N, Garrido A, Acevedo I, Valladares L. In vitro effect of soy isoflavone and equol on soluble CD40L release stimulated by ristocetin in platelets from postmenopause women. JBiSE. 2015; 8:24–30.